Exchange: NASDAQ·Updated 07:53 PM EST
COGT logo

COGT Cogent Biosciences Inc

$26.72
$1.03
(3.69%)
Today
Closed $26.72
$0.485
(1.81%)
After Hours
EarningsFeb 16
Mkt Cap$4.65B
Vol2.13M

About COGT

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
71

Bullish Sentiment

How do you feel about COGT?

StMichaelTwits
$COGT $INO I betted large INO would get approval, and for tomorrow I bet $CYTK gets approval and COGT imo 85% it will get approval in a few weeks..dang Christmas coming early folks.
5
BiotechSwings
12 days out and $COGT is still sitting near the lows into its first real decision imo Nov 30 PDUFA, bezuclastinib plus sunitinib in GIST after imatinib PEAK did 16.5 months median PFS vs 9.2 alone, hazard ratio 0.50, and FDA said no advisory committee planned trading 28.61 today, up 2.7% off a 27.85 close, down about 9.6% in five sessions and under the 50 day near 31.10 that is a discount into a clean clock, not a broken story ngl
4
PolycarpFX
$COGT this week’s Biotech report just dropped. Cogent is one of the names discussed along with 9 other setups as we go deeper into Q4 $XBI
1
1
GoImugene
$COGT Nice to see that some call options were bought today. December 28 calls. I suspect there will be more!!
3
StMichaelTwits
$COGT I am holding for a nice payday in 12 days. Yesterday.. Competitive Advantage. Robbins argued that bezuclastinib’s high selectivity and lack of central nervous system (CNS) penetration give it a tolerability edge over competing therapies like Blueprint Medicines' Ayvakit. Cogent Biosciences’ leadership—including CEO Andrew Robbins and Chief Scientific Officer John Robinson—expressed strong confidence in bezuclastinib's safety profile during yesterday’s investor conferences. Management directly addressed investor questions regarding liver enzyme elevations and potential FDA label language, emphasizing that the clinical data across more than 1,000 patients supports a favorable and predictable safety profile
3
BiotechSwings
Last week of the three is one day doing all the work Nov 30 $COGT bezuclastinib plus sunitinib in GIST after imatinib, Priority Review, PEAK did 16.5 months median PFS vs 9.2 Nov 30 Vertex povetacicept in IgAN, Priority Review on the accelerated path, RAINIER cut proteinuria 52% from baseline that is the hard date list through Dec 6. Vanda on Dec 12 is next after it imo
3
Skoufc1
$COGT if we get black label we go down 40%. How about if we get a good approval november 30th? And then again December 30th?
2
StMichaelTwits
$COGT CEO just got off the questioning..👇💎💪 Jefferies analyst Faisal Khurshid pressed Robbins heavily on investor jitters regarding potential hepatotoxicity warnings on the drug's label. • No Severe Liver Events. Robbins emphasized that across all trials (from 100 mg in NonAdvSM to 600 mg in GIST), there were zero cases of liver failure, liver transplants, serious clinical liver adverse events, or Hy's Law. Elevated transaminases were lab abnormalities that returned to baseline without intervention, after dose reduction, or after stopping treatment. • Routine Monitoring Accepted. He noted that blood lab monitoring is already routine among oncologists and hematologists and will not act as a commercial barrier. • Combination Precedent. Addressing whether a black box warning from its GIST combo partner (sunitinib) could carry over onto bezuclastinib's label, Robbins noted that the FDA evaluates risk-benefit case by case without a rigid rule. Warning label on for last 20yrs .👍
2
ZackInvest008
$COGT Choppy. Closes over 30 to end the week. Expect run up to start next week. Mark this post to show how wrong I always am, for future reference.
2
BiotechSwings
Nov 30 PDUFA. $COGT bezuclastinib plus sunitinib in GIST PEAK was 16.5 months vs 9.2. today dip is just a cheaper runup imo
2
Phaseline
$COGT One drug, three FDA goal dates. Bezuclastinib + sunitinib in GIST: Nov 30. NonAdvanced systemic mastocytosis: Dec 30. Advanced SM: June 29, 2027. Nov 30 rests on Phase 3 PEAK vs sunitinib alone: median PFS 16.5 vs 9.2 months (HR 0.50), ORR 46% vs 26%. Overall survival was still immature. It has Priority Review, and at acceptance FDA said it planned no AdCom and had identified no review issues. Cash was 791.1M at Sept 30. Cogent guides that this funds operations into late 2028.
1
Skoufc1
$COGT Do we get black box label warning due to combination therapy with Sutnib which already carries one? How does thisnplay out for november 30th? December 30th we should be good for clean approval? Any insight how this plays out for PPS and timeslines and scenarios of labeling?
1
JFais
$COGT - one of 19 names on current DD list (shared in each Weekly Recap) GIST PDUFA in 10 days Non-Advanced SM in a month Advanced SM in late June $4.4B EV compares favorably to conservative $2.5B peak sales across indications IND applications for pan-KRAS & JAK2 V617F in Q4
1
GoImugene
$COGT Looks like a 2000 contract put at strike 24 and a 2000 contract call at strike price 30 were placed( straddle option set up)
1
sks144
$COGT absolutely insane. Literally bleeding out. I can only think of two reasons- fear of equity raise or they think the liver warnings will restrict the labeling
1
Darth_Barrister
$COGT Companies have to hire sales reps before approval so they can hit the ground running. In unusual circumstances, they get surprised with a CRL. In my professional days, I was hired by a company that got a CRL (like 20+ years ago). In my investing days, I think Atara did the same thing and got a CRL. I do not expect a CRL here. I am saying it is rare, but it happens.
Skoufc1
$COGT whats the story? If we get a black label for elevated liver enzymes we go down hard? If we just get a label we are ok? I thought we had a good chance of a clean label? Any thoughts?
Cap_00
$COGT Fairmount has 5-6x since their initial investment. They'd get close to 10x their investment if they're to seek a buyer... I think this gets done after approval....

Advertisement|Remove ads.